Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$120,000.00
Placental Delivery of siRNA via Targeted Lipid Nanoparticles as a Treatment for Preeclampsia
EF 2024-25
Résumé
Preeclampsia (PE) is a disease that affects up to one in ten pregnant individuals worldwide, and it can cause severe complications for both the mother and the baby. Tragically, the only definitive treatment for PE is to terminate the pregnancy, causing even more risks related to preterm birth. PE happens when the placenta does not receive enough blood due to poorly developed vessels, leading to insufficient oxygen and nutrients for the baby. Although the main cause of PE is not fully understood, scientists have proved that in PE, the placenta releases molecules into the bloodstream that impair the normal function of many organs.
This project aims to develop a treatment to reduce one of these harmful molecules, called sEng, by preventing its secretion from the placenta. The strategy consists of packing an instruction code into tiny envelopes (called nanoparticles), which will deliver the message to the placenta to stop secreting sEng. These envelopes will be carefully designed to deliver the code only to the placenta while avoiding other organs to prevent undesirable effects. To test this innovative approach, human placental cells will be housed in advanced chips that mimic the placenta's blood flow and physical forces during PE. These parameters are essential to accurately represent what could happen in the placenta and assess if the treatment will work as intended without causing damage to the organ. Finally, the treatment will be tested on mice to ensure the therapy is safe and effective before advancing to clinical trials.
This could be the first therapy to address the cause of severe complications in PE, allowing the pregnancy to come to term safely while reducing the risks to the mom and the baby. This intervention could also save millions of dollars for healthcare systems in Canada and globally. Furthermore, the nanoparticles and chips obtained from this project could aid other researchers in making better treatments for pregnancy diseases.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
518299
Name
Perez Davalos Luis A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Placental Delivery of siRNA via Targeted Lipid Nanoparticles as a Treatment for Preeclampsia
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Hypertensive Disorders Of Pregnancy; Lipid Nanoparticles; Maternal-Fetal Health; Nanomedicine; Nucleic Acid Therapeutics - Sirna; Organs-On-A-Chip; Preeclampsia; Pregnancy Outcomes; Rna Interference; Targeted Drug Delivery
Abstract
Preeclampsia (PE) is a disease that affects up to one in ten pregnant individuals worldwide, and it can cause severe complications for both the mother and the baby. Tragically, the only definitive treatment for PE is to terminate the pregnancy, causing even more risks related to preterm birth. PE happens when the placenta does not receive enough blood due to poorly developed vessels, leading to insufficient oxygen and nutrients for the baby. Although the main cause of PE is not fully understood, scientists have proved that in PE, the placenta releases molecules into the bloodstream that impair the normal function of many organs.
This project aims to develop a treatment to reduce one of these harmful molecules, called sEng, by preventing its secretion from the placenta. The strategy consists of packing an instruction code into tiny envelopes (called nanoparticles), which will deliver the message to the placenta to stop secreting sEng. These envelopes will be carefully designed to deliver the code only to the placenta while avoiding other organs to prevent undesirable effects. To test this innovative approach, human placental cells will be housed in advanced chips that mimic the placenta's blood flow and physical forces during PE. These parameters are essential to accurately represent what could happen in the placenta and assess if the treatment will work as intended without causing damage to the organ. Finally, the treatment will be tested on mice to ensure the therapy is safe and effective before advancing to clinical trials.
This could be the first therapy to address the cause of severe complications in PE, allowing the pregnancy to come to term safely while reducing the risks to the mom and the baby. This intervention could also save millions of dollars for healthcare systems in Canada and globally. Furthermore, the nanoparticles and chips obtained from this project could aid other researchers in making better treatments for pregnancy diseases.
Competitiondate
202411
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Perez Davalos, Luis A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~